galantamine canon-instruction
galantamine-package-back
galantamine canon-instruction
galantamine-package-back

REMINYL ® (Galantamine)

Clear

Buy Galantamine with the fastest delivery!

Galantamine is an alkaloid that was first isolated from Caucasian snowdrop and some other plants; nowadays, it is usually synthesized chemically.

As with many of these drugs, the history of Galantamine started in the former Soviet Union, when M. D. Mashkovsky and his colleague published their work on the AChE-inhibiting properties of this compound. However, it should also be noted that prior to this, the plants containing Galantamine have also been used in ancient Greece and China for their memory-enhancing effects.

As of now, Galantamine is used for the treatment of a variety of conditions including the following:

 

You can also buy Galantamine for its off-label usage to create lucid dreaming effects.

However, this particular drug comes with many different side effects and contraindications, so please do your research prior to consumption and do never go over the recommended dose.

Produced by Johnson & Johnson, Russia / Janssen, Italy.

Check out more products in Nootropics & Brain Health category!

Dosage and administration

The daily dose can vary depending on the condition.

Side effects

Please do your research to learn more about side effects.

Overdose

Please do not go above 4 mg, when you use the drug for the first time.

Manufacturer

Johnson & Johnson, Russia / Janssen, Italy.

  1. Wilcock et al (2000) Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC27547/
  2. J Olin, L Schneider (2001) Galantamine for Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/11687119
  3. J Coyle, P Kershaw (2001) Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/11230880
  4. T Erkinjuntti (2002) Treatment options: the latest evidence with galantamine (Reminyl) https://www.ncbi.nlm.nih.gov/pubmed/12417370
  5. Small et al (2003) Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer’s disease with cerebrovascular disease https://www.ncbi.nlm.nih.gov/pubmed/12962529
  6. S Mayor (2005) Regulatory authorities review use of galantamine in mild cognitive impairment https://www.ncbi.nlm.nih.gov/pmc/articles/PMC548208/
  7. C Loy, L Schneider (2006) Galantamine for Alzheimer’s disease and mild cognitive impairment https://www.ncbi.nlm.nih.gov/pubmed/16437436
  8. Litvinenko et al (2007) Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson’s disease (open-label controlled trial) https://www.ncbi.nlm.nih.gov/pubmed/18427456
  9. Galvin et al (2008) Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil https://www.ncbi.nlm.nih.gov/pubmed/18317244
  10. Burns et al (2009) Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial https://www.ncbi.nlm.nih.gov/pubmed/19042161
  11. B Seltzer (2010) Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2817936/
  12. Prvulovic et al (2010) Galantamine for Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pubmed/20113148
  13. Wouters et al (2010) Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands https://www.ncbi.nlm.nih.gov/pubmed/20593742
  14. Wattmo et al (2013) Dose and plasma concentration of galantamine in Alzheimer’s disease – clinical application https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580330/
  15. Hager et al (2014) Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937252/
  16. Ohnishi et al (2014) The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer’s Disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979115/
  17. H Mucke (2015) The case of galantamine: repurposing and late blooming of a cholinergic drug https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137937/
  18. Nakano et al (2015) Long-Term Efficacy of Galantamine in Alzheimer’s Disease: The Okayama Galantamine Study (OGS) https://www.ncbi.nlm.nih.gov/pubmed/26401696
  19. Matsuzono (2015) Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study https://www.ncbi.nlm.nih.gov/pubmed/25624417
  20. Nakagawa et al (2017) Long-term effect of galantamine on cognitive function in patients with Alzheimer’s disease versus a simulated disease trajectory: an observational study in the clinical setting https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5402999/

Related products

CORTEXIN ®

$40.00$85.00

Cortexin® is a mixture of neuropeptide fractions, amino acids, vitamins and minerals. Cortexin was shown to provide a normalizing effect on many functions of the brain. It has been used in children and adults for a wide variety of indications including ADHD, TBI and minor cerebral problems. Fast US domestic shipping is available.

CEREBROLYSIN ®

$40.00$145.00

Cerebrolysin is a neurometabolic stimulator based on neuropeptides (20%) and amino acids (80%) isolated from pig brain proteins. Cerebrolysin has all the amino acids which compose the central nervous system; this can explain its numerous additional positive properties. It is usually named as the most effective nootropic to date. Fast US domestic shipping is available.

AMINALON (GABA)

$7.00$9.00

Aminalon® is a substance with nootropic and psychostimulatory qualities. The active component of Aminalon is Gamma-Aminobutyric acid (GABA). The main property of GABA is that it regulates blood flow in the brain, improves memory, speech, and coordination. Patients suffering from diabetes also notice lowered blood sugar after Aminalon administration.

ADAPTOL ® (Mebicar)

$10.00$46.00

Adaptol® (Mebicar) belongs to a group of non-benzodizepam tranquilizers. It is approved for use by the general public as an anxiolytic and a “daily” tranquilizer, because it does not disturb mental and motor performance. It is also used to aid smoking cessation and to treat ADHD symptoms. Fast US domestic shipping is available.